We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Bet the pharm

6 May 2014 By Robert Cyran

The pharmaceutical firm’s $14 bln sale of its Claritin-to-Coppertone business frees cash for developing a potentially breakthrough cancer medicine. With the company’s odds for success better than in years, selling high and doubling down on possible blockbusters seems a smart bet.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)